441 related articles for article (PubMed ID: 29083977)
1. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
[TBL] [Abstract][Full Text] [Related]
2. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and Treatment of Osteoporosis Before and After Fracture: A Side-by-Side Analysis of Commercially Insured and Medicare Advantage Osteoporosis Patients.
Weaver J; Sajjan S; Lewiecki EM; Harris ST
J Manag Care Spec Pharm; 2017 Jul; 23(7):735-744. PubMed ID: 28650253
[TBL] [Abstract][Full Text] [Related]
4. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
[TBL] [Abstract][Full Text] [Related]
5. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
[TBL] [Abstract][Full Text] [Related]
6. Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population.
Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
Osteoporos Int; 2017 Aug; 28(8):2485-2494. PubMed ID: 28536737
[TBL] [Abstract][Full Text] [Related]
7. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis.
Liu J; Guo H; Rai P; Pinto L; Barron R
Osteoporos Int; 2018 Nov; 29(11):2409-2417. PubMed ID: 30022254
[TBL] [Abstract][Full Text] [Related]
8. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.
Wang Z; Ward MM; Chan L; Bhattacharyya T
Osteoporos Int; 2014 Aug; 25(8):2109-16. PubMed ID: 24846316
[TBL] [Abstract][Full Text] [Related]
9. Utilization of osteoporosis medication after a fragility fracture among elderly Medicare beneficiaries.
Yusuf AA; Matlon TJ; Grauer A; Barron R; Chandler D; Peng Y
Arch Osteoporos; 2016 Dec; 11(1):31. PubMed ID: 27696099
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Martin KE; Yu J; Campbell HE; Abarca J; White TJ
J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
[TBL] [Abstract][Full Text] [Related]
11. Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug plan.
Ward MA; Xu Y; Viswanathan HN; Stolshek BS; Clay B; Adams JL; Kallich JD; Fine S; Saag KG
Osteoporos Int; 2013 Apr; 24(4):1195-206. PubMed ID: 23100119
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Cost of Subsequent Fractures Among U.S. Patients with an Incident Fracture.
Weaver J; Sajjan S; Lewiecki EM; Harris ST; Marvos P
J Manag Care Spec Pharm; 2017 Apr; 23(4):461-471. PubMed ID: 28345441
[TBL] [Abstract][Full Text] [Related]
13. The impact of teriparatide adherence and persistence on fracture outcomes.
Yu S; Burge RT; Foster SA; Gelwicks S; Meadows ES
Osteoporos Int; 2012 Mar; 23(3):1103-13. PubMed ID: 22159748
[TBL] [Abstract][Full Text] [Related]
14. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
15. Declining trend in osteoporosis management and screening following vertebral compression fractures - a national analysis of commercial insurance and medicare advantage beneficiaries.
Malik AT; Retchin S; Phillips FM; Xu W; Peters K; Yu E; Khan SN
Spine J; 2020 Apr; 20(4):538-546. PubMed ID: 31683068
[TBL] [Abstract][Full Text] [Related]
16. Adherence to treatment of primary osteoporosis and its association to fractures--the Swedish Adherence Register Analysis (SARA).
Landfeldt E; Ström O; Robbins S; Borgström F
Osteoporos Int; 2012 Feb; 23(2):433-43. PubMed ID: 21286686
[TBL] [Abstract][Full Text] [Related]
17. Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis.
Bonafede MM; Shi N; Bower AG; Barron RL; Grauer A; Chandler DB
Osteoporos Int; 2015 Mar; 26(3):1203-12. PubMed ID: 25567774
[TBL] [Abstract][Full Text] [Related]
18. Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment.
Modi A; Tang J; Sen S; Díez-Pérez A
Curr Med Res Opin; 2015 Apr; 31(4):767-77. PubMed ID: 25708648
[TBL] [Abstract][Full Text] [Related]
19. Osteoporosis Medications Prevent Subsequent Fracture in Frail Older Adults.
Chattaris T; Oh G; Gouskova NA; Kim DH; Kiel DP; Berry SD
J Bone Miner Res; 2022 Nov; 37(11):2103-2111. PubMed ID: 36168189
[TBL] [Abstract][Full Text] [Related]
20. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
